Page 3 - Eric Benevich News Today

Neurocrine Biosciences (NASDAQ:NBIX – Get Rating) had its target price cut by Barclays from $131.00 to $125.00 in a research note issued to investors on Thursday, The Fly reports. Several other research analysts have also recently issued reports on NBIX. StockNews.com initiated coverage on Neurocrine Biosciences in a report on Thursday, March 16th. They issued […]

Neurocrine Biosciences (NASDAQ:NBIX – Get Rating) had its target price decreased by Mizuho from $116.00 to $111.00 in a research note released on Thursday, The Fly reports. Other research analysts also recently issued reports about the company. Evercore ISI upgraded Neurocrine Biosciences from an in-line rating to an outperform rating and set a $130.00 target […]

Shell Asset Management Co. cut its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Rating) by 15.2% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 4,533 shares of the company’s stock after selling 811 shares during the quarter. Shell Asset Management Co.’s […]

Canandaigua National Corp trimmed its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Rating) by 8.3% during the 4th quarter, HoldingsChannel.com reports. The firm owned 1,735 shares of the company’s stock after selling 157 shares during the period. Canandaigua National Corp’s holdings in Neurocrine Biosciences were worth $207,000 as of its most recent filing with […]

Larson Financial Group LLC lifted its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Rating) by 20.2% in the fourth quarter, HoldingsChannel reports. The firm owned 2,331 shares of the company’s stock after purchasing an additional 391 shares during the period. Larson Financial Group LLC’s holdings in Neurocrine Biosciences were worth $278,000 at the end […]

Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Rating) – Investment analysts at William Blair boosted their Q1 2023 earnings per share (EPS) estimates for Neurocrine Biosciences in a note issued to investors on Tuesday, April 18th. William Blair analyst M. Minter now expects that the company will post earnings of $0.71 per share for the quarter, […]

Neurocrine Biosciences (NASDAQ:NBIX – Get Rating) had its target price decreased by Wedbush from $131.00 to $128.00 in a research report sent to investors on Monday morning, Benzinga reports. Wedbush currently has an outperform rating on the stock. Wedbush also issued estimates for Neurocrine Biosciences’ Q1 2023 earnings at $0.71 EPS, Q4 2023 earnings at […]

Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Rating) have received an average recommendation of “Moderate Buy” from the twenty research firms that are covering the company, Marketbeat Ratings reports. Five investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating […]

Hanseatic Management Services Inc. bought a new stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Rating) in the fourth quarter, HoldingsChannel.com reports. The institutional investor bought 4,559 shares of the company’s stock, valued at approximately $545,000. Neurocrine Biosciences comprises approximately 1.4% of Hanseatic Management Services Inc.’s investment portfolio, making the stock its 16th […]

Canaccord Genuity Group upgraded shares of Neurocrine Biosciences (NASDAQ:NBIX – Get Rating) from a hold rating to a buy rating in a research report report published on Thursday morning, MarketBeat.com reports. Canaccord Genuity Group currently has $132.00 price target on the stock, up from their previous price target of $124.00. NBIX has been the subject […]